Twelve Hallmarks of Aging Drive Alzheimer's and Point to Rejuvenation Therapies
A comprehensive review maps how genomic instability, mitochondrial failure, and cellular senescence fuel Alzheimer's disease, and outlines emerging rejuvenation strategies.
Summary
This review organizes the twelve hallmarks of aging into four functional clusters — genomic and epigenomic instability, proteostasis and organelle dysfunction, cellular fate and regenerative decline, and cellular senescence — and examines how each drives Alzheimer's disease. The authors highlight recent mechanistic discoveries, including topoisomerase-linked DNA mutations found in 65% of Alzheimer's neurons, sex-specific tau pathology mediated by the deubiquitinase USP11, and LINE-1 retrotransposon reactivation in microglia. They then survey emerging rejuvenation strategies such as young plasma factors, stem cell secretomes, and extracellular vesicles that can address these hallmarks systemically, arguing that targeting aging biology upstream of amyloid and tau pathology may offer more durable disease modification than current symptomatic therapies.
Detailed Summary
Alzheimer's disease (AD) affects an estimated 57 million people worldwide and is projected to exceed 139 million cases by 2050, carrying an annual global economic burden surpassing USD 2.8 trillion. Despite decades of research, approved therapies remain largely symptomatic. This review by Izrael and Frenkel, published in Neural Regeneration Research, takes a systems-biology perspective by reorganizing the canonical twelve hallmarks of aging into four mechanistically coherent clusters and methodically mapping how each accelerates AD pathogenesis, before surveying innovative therapeutic strategies aimed at reversing them.
The first cluster — genomic and epigenomic instability — encompasses accumulating DNA damage, telomere attrition, and epigenetic dysregulation. Single-cell whole-genome sequencing of AD neurons revealed a significantly elevated burden of somatic single-nucleotide variants and short insertion/deletion mutations versus neurotypical controls, with a distinctive oxidative-damage and topoisomerase-1-linked mutational signature present in 65% of AD neurons but only 5% of controls. Separately, single-nucleus RNA sequencing identified increased somatic gene fusions in excitatory AD neurons alongside disrupted three-dimensional genome architecture mediated by elevated cohesin levels. On the epigenetic front, histone hyperacetylation (H3K27ac and H3K9ac) in AD postmortem brains correlated with upregulated transcriptional regulators and worsened neurodegeneration in a Drosophila model. LINE-1 retrotransposon reactivation in microglia impaired amyloid-β phagocytosis and induced inflammatory gene programs, while pathogenic tau triggered heterochromatin decondensation and transposable-element activation, generating double-stranded RNA that drove neuroinflammation across human, mouse, and fly systems.
The second cluster covers proteostasis and organelle dysfunction. Ubiquitin-proteasome system (UPS) components in cerebrospinal fluid begin rising up to two decades before symptom onset in dominantly inherited AD, inversely tracking neurodegeneration imaging metrics. A sex-specific mechanism was identified whereby elevated USP11 deubiquitinase levels in females enhance tau pathology through deubiquitination-dependent acetylation. Mitochondrial dysfunction is proposed as potentially upstream of amyloid pathology: astrocytic mitochondrial failure disrupts fatty acid oxidation, promotes lipid droplet accumulation, activates STAT3-driven astrocyte reactivity, and impairs myelination, mirroring AD phenotypes. NAD+ replenishment via nicotinamide mononucleotide restored synaptic integrity in AD models through the ATF4-mediated mitochondrial unfolded protein response. Impaired autophagic flux — across neurons, astrocytes, and microglia — further prevents clearance of amyloid-β, tau, and damaged mitochondria, with multiple plant-derived compounds (hederagenin, magnolol) shown to restore autophagy and reduce plaque burden in APP/PS1 mice.
The third cluster addresses cellular fate and regenerative decline. In AD, hippocampal neurogenesis is markedly suppressed due to chronic inflammation, stem cell exhaustion, and a shift toward gliogenic fate. Altered intercellular signaling — via inflammatory cytokines, extracellular vesicles, and impaired trophic support — further disrupts neural resilience. The fourth cluster, systemic homeostatic imbalance (encompassing cellular senescence and altered intercellular communication), encompasses the senescence-associated secretory phenotype (SASP), which floods the brain microenvironment with pro-inflammatory cytokines and matrix-degrading enzymes that amplify neurodegeneration.
Against this backdrop, the review highlights rejuvenation strategies designed to address these hallmarks systemically. Young plasma factors, stem cell secretomes, and their derived extracellular vesicles carry bioactive cargo — growth factors, microRNAs, and signaling proteins — capable of restoring proteostasis, promoting neurogenesis, suppressing neuroinflammation, and improving mitochondrial function. The authors also note key biological modifiers of AD progression, including APOE genotype (APOE4 worsening epigenetic and telomeric vulnerability), biological sex (females showing USP11-driven tau vulnerability and more pronounced telomere shortening), and the NAD+/sirtuin axis, all of which represent candidate therapeutic targets. The authors call for clinical trials integrating rejuvenation biologics with established senolytic and autophagy-enhancing agents to achieve multi-hallmark disease modification.
Key Findings
- A topoisomerase-1-linked mutational signature was found in 65% of Alzheimer's disease neurons versus only 5% of neurotypical control neurons in single-cell whole-genome sequencing.
- UPS biomarkers in cerebrospinal fluid begin rising up to two decades before symptom onset in dominantly inherited Alzheimer's disease, inversely correlating with neurodegeneration imaging metrics.
- Elevated USP11 deubiquitinase in females enhances tau pathology via deubiquitination-dependent acetylation, identifying a sex-specific proteostasis vulnerability in Alzheimer's disease.
- LINE-1 retrotransposon reactivation in Alzheimer's microglia impaired amyloid-β phagocytosis; CRISPR activation of LINE-1 in iPSC-derived microglia induced inflammatory gene programs and Alzheimer's disease risk gene expression.
- Pathogenic tau triggers heterochromatin decondensation and activates transposable elements, generating double-stranded RNA that drives neuroinflammation across human, mouse, and Drosophila systems.
- NAD+ replenishment with nicotinamide mononucleotide restored synaptic integrity and reduced neuronal loss in Alzheimer's models via ATF4-mediated mitochondrial unfolded protein response.
- APOE4 genotype amplified telomere-driven white matter vulnerability and aberrant chromatin signatures in CD8+ T cells and monocytes, suggesting a convergence of genetic and epigenetic risk.
Methodology
This is a narrative review, not an original experimental study; it synthesizes findings from single-cell whole-genome sequencing, single-nucleus RNA sequencing, postmortem brain analyses, longitudinal cohort data (ADNI, NCT00106899), iPSC-derived cell models, mouse models (APP/PS1, 5×FAD), Drosophila systems, Mendelian randomization studies, and bioinformatics analyses. No primary data were generated by the authors. Evidence quality varies across cited studies — some are mechanistic preclinical findings and others are cross-sectional or longitudinal human cohort analyses. Statistical details and sample sizes are drawn from the cited primary literature rather than reported uniformly.
Study Limitations
As a narrative review, the paper does not perform a systematic search or meta-analysis and may be subject to selection bias in the cited literature. Many of the rejuvenation strategies discussed (young plasma factors, secretome therapies, extracellular vesicles) remain in preclinical or very early clinical stages with limited human safety and efficacy data. One author is affiliated with a biotechnology company (Leverage Bio Ltd.), which may represent a potential conflict of interest, particularly in sections advocating secretome and extracellular vesicle-based therapeutics.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: